Demethoxycurcumin

Cat. No.: HY-N0006
CAS No.: 22608-11-3
Molecular Formula: C_{20}H_{18}O_{5}
Molecular Weight: 338.35
Target: Apoptosis; Autophagy
Pathway: Apoptosis; Autophagy
Storage:
- Powder: -20°C for 3 years, 4°C for 2 years, In solvent: -80°C for 6 months, -20°C for 1 month

**SOLVENT & SOLUBILITY**

<table>
<thead>
<tr>
<th>In Vitro</th>
<th>DMSO: 100 mg/mL (295.55 mM; Need ultrasonic)</th>
<th>H_{2}O: &lt; 0.1 mg/mL (insoluble)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparing Stock Solutions</td>
<td>Solvent</td>
<td>Mass</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mM</th>
<th>2.9555 mL</th>
<th>14.7776 mL</th>
<th>29.5552 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mM</td>
<td>0.5911 mL</td>
<td>2.9555 mL</td>
<td>5.9110 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2956 mL</td>
<td>1.4778 mL</td>
<td>2.9555 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo:
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 3.25 mg/mL (9.61 mM); Clear solution

**BIOLOGICAL ACTIVITY**

Description:
Demethoxycurcumin (Curcumin II) is a major active curcuminoid; possess anti-inflammatory properties; also exert cytotoxic effects in human cancer cells via induction of apoptosis. IC_{50} value: Target: in vitro: DMC significantly decreased NO secretion by 35-41% in our inflamed cell model. Decrease in NO production by DMC was concomitant with down-regulation of iNOS at mRNA and protein levels compared to proinflammatory cytokine cocktail and LPS-treated controls. Mechanism of action of DMC may be partly due to its potent inhibition of the iNOS pathway [1]. BDMCCN has the strongest inhibitory activity toward BACE-1 with 17 μM IC_{50}, which was 20 and 13 times lower than those of CCN and DMCCN respectively [2]. Genes associated with DNA damage and repair, cell-cycle check point and apoptosis could be altered by DMC; in particular, 144 genes were found up-regulated and 179 genes down-regulated in NCI-H460 cells after exposure to DMC [3]. in vivo: At low doses, both the curcuminoid mixture and curcumin I did not affect brain stimulation reward, whereas, higher doses increased ICSS thresholds. Curcumin II and curcumin III did
not affect brain stimulation reward at any doses. Subthreshold doses of the curcuminoid mixture and curcumin I inhibited the reward-facilitating effect of morphine.

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

www.MedChemExpress.com